Quarta Stefano, Santarpino Giuseppe, Carluccio Maria Annunziata, Calabriso Nadia, Maffia Michele, Siculella Luisa, Damiano Fabrizio, Madonna Rosalinda, Massaro Marika
Department of Biological and Environmental Sciences and Technologies (DISTEBA), University of Salento, 73100 Lecce, Italy; Department of Surgical, Medical, Molecular Pathology and Critical Care Sciences, University of Pisa, Via Savi 10, 56126 Pisa, Italy.
Cardiovascular Center, Paracelsus Medical University, 90471 Nuremberg, Germany; GVM Care & Research, Città di Lecce Hospital, 73100 Lecce, Italy; Cardiac Surgery Unit, Department of Experimental and Clinical Medicine, University "Magna Graecia", 88100 Catanzaro, Italy.
Vascul Pharmacol. 2023 Oct;152:107210. doi: 10.1016/j.vph.2023.107210. Epub 2023 Aug 21.
Aortic stenosis (AS) is a dynamic degenerative process that shares many pathophysiological features with atherogenesis, from initial proinflammatory calcification and focal thickening of the valve leaflets to obstruction of left ventricular outflow due to superimposed of severe calcification and immobilization of the valve leaflets. As the prevalence increases with age, AS is expected to become one of the most common heart diseases worldwide. In both obese and nonobese patients, persistent thickening of epicardial adipose tissue (EAT) is associated with a shift in its normal metabolic functions toward a dysmetabolic and proatherogenic phenotype that may impair the physiology of adjacent coronary arteries and promote the occurrence of coronary atherosclerosis. In tight analogy with atherosclerosis, recent clinical evidence indicates that EAT may also exert a deleterious role in promoting AS and contributing to myocardial dysfunction, leading to increased health risk for elderly patients with AS and an economic burden on the health care system. This review discusses the clinical and pathologic evidence for the association between EAT and AS and concomitant left ventricular hypertrophy, and provides new insights for the future direction of AS diagnosis and treatment.
主动脉瓣狭窄(AS)是一种动态退行性病变过程,与动脉粥样硬化有许多共同的病理生理特征,从最初的促炎性钙化和瓣叶局灶性增厚,到因严重钙化叠加和瓣叶固定导致左心室流出道梗阻。随着患病率随年龄增加,AS有望成为全球最常见的心脏病之一。在肥胖和非肥胖患者中,心外膜脂肪组织(EAT)持续增厚与其正常代谢功能向代谢紊乱和促动脉粥样硬化表型转变有关,这可能损害相邻冠状动脉的生理功能并促进冠状动脉粥样硬化的发生。与动脉粥样硬化极为相似,最近的临床证据表明,EAT在促进AS和导致心肌功能障碍方面也可能发挥有害作用,从而增加AS老年患者的健康风险,并给医疗保健系统带来经济负担。本综述讨论了EAT与AS及伴随的左心室肥厚之间关联的临床和病理证据,并为AS诊断和治疗的未来方向提供了新见解。